U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06842199) titled 'Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis' on Feb. 18.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Plaque Psoriasis Patients
Intervention:
DRUG: ICP-488 Tablets
Eligible patients will receive ICP-488 orally as per the protocol
DRUG: ICP-488 Placebo
Eligible patients will receive ICP-488 Placebo orally as per the proto...